Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival

Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival

ABSTRACT Objective: To evaluate the association between the patients’ characteristics and the development of endocrine toxicity and to assess the association between endocrine-related adverse effects (ERAE) development and mortality. Subjects and methods: A retrospective observational study was co...

Full description

Bibliographic Details
Main Authors:	Mariana Ornelas, Marta Borges-Canha, Pedro Gouveia, Margarida Ferreira, Eduarda Resende, Maritza Sá, Silvestre Abreu
Format:	Article
Language:	English
Published:	Brazilian Society of Endocrinology and Metabolism 2023-07-01
Series:	Archives of Endocrinology and Metabolism
Subjects:	Immune checkpoint inhibitors immunotherapy endocrine system diseases drug-related side effects and adverse reactions
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972023000600208&lng=en&tlng=en

Similar Items

Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
by: Naoko Okura, et al.
Published: (2020-06-01)

Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival
by: Lisa Yang, et al.
Published: (2024-04-01)

Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports
by: Meng H. Tan, et al.
Published: (2019-01-01)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
by: Deborah L. Burnett, et al.
Published: (2022-07-01)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
by: Cristiane J. Gomes-Lima, et al.
Published: (2023-09-01)

Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study
by: José A. Gómez-Puerta, et al.
Published: (2022-06-01)

Development of three endocrinopathies under nivolumab therapy
by: Anastasia A. Glibka, et al.
Published: (2023-02-01)

Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer
by: Ruth Percik, et al.
Published: (2023-04-01)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01)

Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
by: Lian Duan, et al.
Published: (2020-04-01)

Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience
by: Baptiste Bonnet, et al.
Published: (2024-02-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors
by: Lian DUAN, et al.
Published: (2019-10-01)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
by: Zeng Zhang, et al.
Published: (2022-10-01)

Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center
by: Anam A. Mazharuddin, et al.
Published: (2022-11-01)

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience
by: Juřica Jan, et al.
Published: (2022-06-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
by: Hanna Karhapää, et al.
Published: (2022-02-01)

Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
by: Hyemi Kwon, et al.
Published: (2022-12-01)

Endocrine side effects of immune checkpoint inhibitors
by: Zulma Cardona, et al.
Published: (2023-05-01)

Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice
by: Liliana Gabriela Popa, et al.
Published: (2024-02-01)

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
by: Lorena Villa-Crespo, et al.
Published: (2022-02-01)

Research hot spots and trends in endocrine-related adverse events caused by immune checkpoint inhibitors: a bibliometric analysis and visualization research
by: Jun Zhao, et al.
Published: (2024-04-01)

Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
by: Almog Shalit, et al.
Published: (2023-01-01)

Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review
by: Carlo Augusto Mallio, et al.
Published: (2023-05-01)

Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives
by: Chan KK, et al.
Published: (2022-05-01)

Immune checkpoint inhibitor‐mediated psoriasis treated with biologics
by: Pei Ming Yeo, et al.
Published: (2023-06-01)

Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01)

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0
by: Rodrigo Ramella Munhoz, et al.
Published: (2022-10-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients
by: Viswam S. Nair, et al.
Published: (2021-01-01)

Imaging assessment of toxicity related to immune checkpoint inhibitors
by: Antonia M. Berz, et al.
Published: (2023-02-01)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
by: Hans Urban, et al.
Published: (2022-01-01)

The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
by: Gerard Milano, et al.
Published: (2021-01-01)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
by: Stavroula A. Paschou, et al.
Published: (2022-03-01)

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
by: Sung Wook Hwang, et al.
Published: (2023-10-01)

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
by: Nicia I. Profili, et al.
Published: (2023-08-01)

Neurosarcoidosis following Immune Checkpoint Inhibition
by: Anastasie M. Dunn-Pirio, et al.
Published: (2018-07-01)

A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors
by: Oren Levine, et al.
Published: (2017-08-01)

Abdelazim and Sakiyeva endocrinopathy associated with polycystic ovary syndrome: Case reports
by: Ibrahim A Abdelazim, et al.
Published: (2019-01-01)